Review literature on uterine carcinosarcoma

Singh, Vikram

doi:10.4103/0973-1482.138197

Cited by 44 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, except when information on survival status or duration was not available (18/48), the median survival time was 15 months. Although this result was higher than those of previous reports, it was a dismal survival outcome compared to the median survival of 25–30 months for resectable conventional PDAC [ 37 , 38 ].…”

Section: Discussioncontrasting

confidence: 70%

“…Still et al [ 15 ] showed metastatic sarcoma in a liver metastatic lesion. In the carcinosarcoma originated from organs other than pancreas, the majority component of metastasis is carcinomatous, showing a similar metastasis pattern [ 38 - 40 ]. Although Still et al [ 15 ] explained that carcinoma was fully treated with adjuvant chemotherapy, the remnant sarcomatous component resulted in metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy

Lee

Cho

Jung

et al. 2023

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

Pancreatic carcinosarcoma is a very rare malignancy with a poor prognosis. Because of these characteristics, a treatment strategy for it has not been established yet. The aim of this study was to establish a therapeutic strategy for pancreatic carcinosarcoma. We reviewed data of a 65-year-old female patient who was diagnosed with pancreatic carcinosarcoma through endoscopic ultrasound-guided fine needle aspiration biopsy before surgery. For literature review, we searched PubMed using terms of "Pancreatic" or "Pancreas" and "carcinosarcoma" or "carcinosarcomatous". The patient received 11 cycles of neoadjuvant treatment with leucovorin, fluorouracil, irinotecan, oxaliplatin and pembrolizumab because the tumor was borderline resectable. She underwent stereotactic ablative body radiotherapy (SABR) with 35 Gy in 5 fractions, followed by robotic pylorus-preserving pancreaticoduodenectomy. After surgery, the patient received adjuvant chemotherapy in the same regimen as before surgery. She is alive without any recurrence. Among 48 patients within 33 available papers, the median survival time was 15 months. The survival rate of patients who received adjuvant chemotherapy tended to be higher than that of those who did not receive adjuvant chemotherapy, although the difference was not statistically significant (median survival, 47 vs. 15 months; p = 0.485). Three patients who received neoadjuvant chemotherapy had a survival period of 13-23.5 months. Surgery with lymphadenectomy, adjuvant therapy, and neoadjuvant therapy are thought to help improve survival outcomes. Modern treatment approaches for conventional pancreatic ductal adenocarcinoma could be applied to pancreatic carcinosarcoma.

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy

Lee

Cho

Jung

et al. 2023

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

show abstract

“…Previous exposure to radiation is the most commonly associated etiological factor of carcinosarcoma, 9 particularly after radiotherapy for malignancies of the uterine cervix, 3 as in the present case. Two mechanisms were proposed for the pathogenesis of radiation-induced malignancies: (a) radiation: single and double strand DNA breaks, which lead to gene mutation and malignant transformation of the radiated cells; and (b) the bystander or abscopal effect: the inflammatory cytokines released from the radiated cells induce increased reactive oxygen species, causing DNA damage.…”

Section: Discussionsupporting

confidence: 49%

“…Data on adjuvant chemotherapy and/or radiation therapy are limited and often conflicting, although the 2016 National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant treatment in most stages of UCS. 1 4 9 Future genetic characterization may offer the potential to increase the therapeutic options, improving the prognosis of this rare type of cancer. 5 6 In the present case, the patient was not able to complete the adjuvant therapy and the progression of the disease was remarkable.…”

Section: Discussionmentioning

confidence: 99%

Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma

Moreira-Barros

Huang

Tsai

2018

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective To describe a case of radiation-induced uterine carcinosarcoma 6 years after a cervical squamous cell carcinoma treatment, which imposed some diagnostic and management challenges. Case Report A 57-year-old woman with a history of pelvic chemoradiotherapy ∼ 6.5 years before the event described in this study, following an International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer, presented with a cervical mass, involving the uterine cavity, the cervical canal and the upper two thirds of the vagina. The biopsy showed a poorly differentiated carcinoma, and a positron emission tomography (PET) scan excluded distant metastasis, although it was unable to define the origin of the tumor as either a new primary malignancy of the endometrium/cervix or as a cervical recurrence. Surgical staging procedure was performed, and the diagnosis was endometrial carcinosarcoma, FIGO stage IIB. The patient was not able to complete the adjuvant therapy, and the progression of the disease was remarkable. Conclusion The present case highlights one of the less common but more serious consequences of radiotherapy for cervical cancer, which has an increasing incidence in younger women, raising concerns about the long-term consequences of its management.

show abstract

“…On microscopic examination, it was characterized by the coexistence of malignant epithelial and mesenchymal components, which posed significant challenges for accurate identification and classification [ 7 ]. MMMTs are regarded for their molecular and genetic heterogeneity, which contributes to the variability in clinical behavior and treatment responsiveness [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Challenges in diagnosis and treatment: a case report on a mixed malignant Müllerian tumor

Saenz,

Fernández,

Cóbar

2023

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Mixed malignant Müllerian tumors (MMMTs) are rare and aggressive neoplasms made up of both carcinomatous and sarcomatous components that primarily appear in the female reproductive tract. The cellular origin of this malignancy has eluded advancements in molecular and immunohistochemical techniques contributing to the limited diagnostic and therapeutic strategies. This case report presents a 41-year-old female with a history of abnormal uterine bleeding and dysmenorrhea who was later diagnosed with an MMMT. This case highlights the importance of considering MMMTs in patients with a long-standing history of abnormal uterine bleeding because the prompt recognition and diagnosis of this condition may lead to an improved overall survival for these patients.

show abstract

Review literature on uterine carcinosarcoma

Cited by 44 publications

References 0 publications

Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy

Collective review of pancreatic carcinosarcoma, a very rare pancreatic malignancy

Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma

Challenges in diagnosis and treatment: a case report on a mixed malignant Müllerian tumor

Contact Info

Product

Resources

About